<DOC>
	<DOCNO>NCT00046904</DOCNO>
	<brief_summary>RATIONALE : Etanercept substance study treatment cachexia ( weight loss ) anorexia ( lack appetite ) patient cancer . It yet know whether etanercept effective improve cancer-related cachexia anorexia . PURPOSE : Randomized phase III trial determine effectiveness etanercept treat cancer-related cachexia anorexia patient advance cancer .</brief_summary>
	<brief_title>Etanercept Treating Cancer-Related Cachexia Anorexia Patients With Advanced Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare etanercept vs placebo treatment cancer-related cachexia anorexia , term weight measurement rate weight change , patient advance malignancy . - Determine effect drug nausea vomit patient . - Assess functional status appetite patient treat drug . - Assess quality life patient treated drug . - Determine toxic effect drug patient . - Determine whether drug prolongs survival patient . OUTLINE : This randomize , double-blind , placebo-controlled , multicenter study . Patients stratify accord primary malignant disease ( lung vs gastrointestinal v ) , severity weight loss ( le 4.6 kg v least 4.6 kg ) , plan concurrent chemotherapy ( yes v ) , age ( le 50 v 50 ) , gender , plan use megestrol progestational agent ( yes v ) , GBU Prognostic Index ( good v bad vs unsure ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive etanercept subcutaneously ( SC ) twice weekly . - Arm II : Patients receive placebo SC twice weekly . Treatment arm continue maximum 24 week absence disease progression unacceptable toxicity . Quality life assess baseline , weekly 1 month , monthly treatment . Patients follow every 6 month 5 year . PROJECTED ACCRUAL : A total 274 patient ( 137 per treatment arm ) accrue study within 19 month .</detailed_description>
	<mesh_term>Anorexia</mesh_term>
	<mesh_term>Cachexia</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm malignancy except brain cancer If patient multiple primary unknown primary , currently active cancer brain cancer Disease consider incurable available therapy No clinical evidence ascites Weight loss least 5 pound ( 2.3 kg ) within past 2 month ( exclude perioperative weight loss ) and/or estimate caloric intake less 20 cal/kg daily Weight gain determine physician beneficial Patient perceives weight loss problem PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy More 3 month Hematopoietic Not specify Hepatic Not specify Renal Not specify Cardiovascular No poorly control congestive heart failure No poorly control hypertension No pacemaker , implanted defibrillator , stent , metal suture material heart great vessel ( patient participate BIA translational portion study ) Gastrointestinal No known mechanical obstruction alimentary tract No malabsorption No intractable vomiting ( 5 episodes/week ) Not concurrently receive tube feeding parenteral nutrition Other Able reliably administer subcutaneous medication twice weekly Alert mentally competent Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy More 1 month since prior infliximab No concurrent live vaccination Chemotherapy Concurrent chemotherapy allow Endocrine therapy At least 1 month since prior adrenal steroid No concurrent adrenal steroid ( inhalant , topical , optical steroid allow ) Concurrent shortterm dexamethasone chemotherapyinduced emesis allow Radiotherapy Concurrent radiotherapy allow Surgery Not specify Other More 1 month since prior etanercept No concurrent evaluation another device inject electrical current body ( patient participate bioelectrical impendance analysis [ BIA ] translational portion study )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>anorexia</keyword>
	<keyword>cachexia</keyword>
</DOC>